Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Non-Current Debt (2022 - 2025)

Historic Non-Current Debt for Immunocore Holdings (IMCR) over the last 4 years, with Q3 2025 value amounting to $392.6 million.

  • Immunocore Holdings' Non-Current Debt rose 53.75% to $392.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.6 million, marking a year-over-year increase of 53.75%. This contributed to the annual value of $391.0 million for FY2024, which is 71442.38% up from last year.
  • Immunocore Holdings' Non-Current Debt amounted to $392.6 million in Q3 2025, which was up 53.75% from $392.1 million recorded in Q2 2025.
  • Immunocore Holdings' 5-year Non-Current Debt high stood at $438.1 million for Q2 2024, and its period low was $47.8 million during Q4 2022.
  • For the 4-year period, Immunocore Holdings' Non-Current Debt averaged around $325.5 million, with its median value being $391.5 million (2025).
  • As far as peak fluctuations go, Immunocore Holdings' Non-Current Debt skyrocketed by 71442.38% in 2024, and later tumbled by 1051.64% in 2025.
  • Over the past 4 years, Immunocore Holdings' Non-Current Debt (Quarter) stood at $47.8 million in 2022, then increased by 0.43% to $48.0 million in 2023, then soared by 714.42% to $391.0 million in 2024, then grew by 0.4% to $392.6 million in 2025.
  • Its Non-Current Debt was $392.6 million in Q3 2025, compared to $392.1 million in Q2 2025 and $391.5 million in Q1 2025.